Review of EMA Approved French Translation for Emtricitabine/Tenofovir disoproxil

The following segments need review. They are presented as they appear as of November 27 2020 in the texts approved by the European Medicines Agency.

Do you need to translate Emtricitabine/Tenofovir disoproxil into French? Download the translation memory for the English French product information texts.

English

Tenofovir is primarily excreted by the kidney by both filtration and an active tubular transport system with approximately 70-80% of the dose excreted unchanged in urine following intravenous administration.

French

Le ténofovir est principalement éliminé par voie rénale, à la fois par filtration et par un système de transport tubulaire actif, environ 70 à 80% de la dose excrétée se retrouvant sous forme inchangée dans l’urine après administration intraveineuse.

Reason

70-80% refers to dose originally administered


English

Overall HIV-1 infection prevention strategy

French

Stratégie globale de prévention de l’infection par le VIH-1

Reason

needs verification


English

While effective viral suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission, a residual risk cannot be excluded.

French

Bien qu’il ait été démontré que l’efficacité virologique d’un traitement antirétroviral réduise sensiblement le risque de transmission du VIH par voie sexuelle, un risque de transmission ne peut être exclu.

Reason

“residual” omitted in French


English

Triple nucleoside therapy

French

Trithérapie comportant deux analogues nucléosidiques et un analogue nucléotidique

Reason

Needs review:

Emtricitabine is a a nucleoside reverse-transcriptase inhibitor (NRTI)

 (analogues nucléosidiques

whereas

Tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor

(analogues nucléotidiques)